Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
TypePublic
HQSummit, US
Founded1986
Size (employees)7,467 (est)+5%
Websitecelgene.com
Celgene Corporation was founded in 1986 and is headquartered in Summit, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Celgene Corporation

Mark J. Alles

Mark J. Alles

Chairman and Chief Executive Officer
Peter N. Kellogg

Peter N. Kellogg

Executive Vice President and Chief Financial Officer
Nadim Ahmed

Nadim Ahmed

President, Hematology & Oncology
Terrie Curran

Terrie Curran

President, Inflammation and Immunology
Rupert Vessey

Rupert Vessey

Executive Vice President and President, Research and Early Development
Jonathan Biller

Jonathan Biller

Executive Vice President and General Counsel
Show more

Celgene Corporation Office Locations

Celgene Corporation has offices in Singapore, Summit and Boudry
Summit, US (HQ)
86 Morris Avenue Summit
Singapore, SG
200 Newton Road #04-01, Newton 200
Boudry, CH
Route de Perreux 1
Show all (3)
Report incorrect company information

Celgene Corporation Financials and Metrics

Celgene Corporation Revenue

Embed Graph
Celgene Corporation's revenue was reported to be $13 b in FY, 2017
USD

Revenue (Q2, 2018)

7.4 b

Gross profit (Q2, 2018)

7.1 b

Gross profit margin (Q2, 2018), %

96.4%

Net income (Q2, 2018)

1.9 b

EBIT (Q2, 2018)

1.7 b

Market capitalization (21-Sep-2018)

61.7 b

Closing stock price (21-Sep-2018)

87.7

Cash (30-Jun-2018)

1.5 b

EV

61.7 b
Celgene Corporation's current market capitalization is $61.7 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

6.5 b7.7 b9.3 b11.2 b13 b

Revenue growth, %

18%21%21%

Cost of goods sold

340.4 m385.9 m420.1 m438 m461 m

Gross profit

6.2 b7.3 b8.8 b10.8 b12.5 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Revenue

2.3 b2.3 b2.5 b2.8 b3 b3 b3.3 b3.3 b3.5 b7.4 b

Cost of goods sold

100.8 m109.9 m105.9 m110.9 m107.7 m113 m111 m118 m135 m261 m

Gross profit

2.2 b2.2 b2.4 b2.6 b2.9 b2.8 b3.2 b3.2 b3.4 b7.1 b

Gross profit Margin, %

96%95%96%96%96%96%97%96%96%96%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

3.2 b4.1 b4.9 b6.2 b7 b

Inventories

340.4 m393.1 m443.4 m497.9 m541 m

Current Assets

7.6 b9.7 b9.4 b10.9 b14.9 b

PP&E

593.4 m642.6 m814.1 m929.8 m1.1 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

2.4 b2.4 b3.2 b3.7 b4.4 b4.5 b6 b4.4 b5.1 b5.5 b5.3 b6.7 b5.5 b2.8 b1.5 b

Inventories

313.3 m347.8 m360 m372 m386.7 m414.3 m420.9 m470.6 m490.4 m507.9 m509 m533 m537 m536 m555 m

Current Assets

7.6 b6.9 b8.1 b8.8 b9.7 b9.9 b10.2 b8.4 b9.2 b9.6 b11.6 b13.1 b14.8 b7.9 b6.9 b

PP&E

592.3 m595.7 m605.1 m623.6 m649.7 m675.2 m702 m840 m854 m891.3 m958 m989 m1 b1.3 b1.3 b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

1.4 b2 b1.6 b2 b2.9 b

Depreciation and Amortization

134 m

Inventories

(89.7 m)(56.5 m)(50.6 m)(55.3 m)(42 m)

Cash From Operating Activities

2.2 b2.8 b2.5 b4 b5.2 b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

1.2 b279.7 m877.5 m1.4 b718.9 m1.1 b1 b800.7 m1.4 b1.6 b941 m2 b3 b846 m1.9 b

Depreciation and Amortization

71.8 m25.5 m52.1 m78.1 m28.1 m57.8 m86.6 m29.2 m58.5 m89.6 m32 m66 m100 m126 m296 m

Inventories

(62.6 m)(7 m)(19.1 m)(33.6 m)7.3 m(19.2 m)(27.1 m)(25.6 m)(45.2 m)(62.3 m)(10 m)(32 m)(37 m)6 m(14 m)

Cash From Operating Activities

1.7 b557.1 m1.1 b2 b856.5 m1.1 b1.4 b974.9 m1.9 b2.6 b853 m2.5 b3.6 b(325 m)904 m
USDY, 2018

EV/EBIT

36.2 x

EV/CFO

68.2 x

EV/FCF

83.8 x

Financial Leverage

9.8 x
Show all financial metrics

Celgene Corporation Operating Metrics

FY, 2016

Active Clinical Studies

52
Show all operating metrics

Celgene Corporation Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Juno TherapeuticsJanuary 22, 2018$9 b
Impact BiomedicinesJanuary 07, 2018
Report incorrect company information

Celgene Corporation Online and Social Media Presence

Embed Graph
Report incorrect company information

Celgene Corporation Company Life and Culture

Report incorrect company information